Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Avelumab versus oxaliplatin-based chemotherapy in Japanese patients with cancer
jRCT2080223417Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Dec 2016
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised trial of avelumab in cancer (3 arms), sponsored by Merck & Co. Started Dec 2016; status: completed.
02
Drugs
avelumab
03
Conditions
cancer
Beyond the preview
Go deeper on jRCT2080223417.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223417.